|
1
|
Drilon A, Sugita H, Sima CS, Zauderer M,
Rudin CM, Kris MG, Rusch VW and Azzoli CG: A prospective study of
tumor suppressor gene methylation as a prognostic biomarker in
surgically resected stage I to IIIA non-small-cell lung cancers. J
Thorac Oncol. 9:1272–1277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morisaki H, Yamanaka I, Iwai N, Miyamoto
Y, Kokubo Y, Okamura T, Okayama A and Morisaki T: CDH13 gene coding
T-cadherin influences variations in plasma adiponectin levels in
the Japanese population. Hum Mutat. 33:402–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung CM, Lin TH, Chen JW, Leu HB, Yang
HC, Ho HY, Ting CT, Sheu SH, Tsai WC, Chen JH, et al: A genome-wide
association study reveals a quantitative trait locus of adiponectin
on CDH13 that predicts cardiometabolic outcomes. Diabetes.
60:2417–2423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hulpiau P and van Roy F: Molecular
evolution of the cadherin superfamily. Int J Biochem Cell Biol.
41:349–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dames SA, Bang E, Haüssinger D, Ahrens T,
Engel J and Grzesiek S: Insights into the low adhesive capacity of
human T-cadherin from the NMR structure of Its N-terminal
extracellular domain. J Biol Chem. 283:23485–23495. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciatto C, Bahna F, Zampieri N, Van
Steenhouse HC, Katsamba PS, Ahlsen G, Harrison OJ, Brasch J, Jin X,
Posy S, et al: T-cadherin structures reveal a novel adhesive
binding mechanism. Nat Struct Mol Biol. 17:339–347. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu T, Qian WJ, Gritsenko MA, Camp DG II,
Monroe ME, Moore RJ and Smith RD: Human plasma N-glycoproteome
analysis by immunoaffinity subtraction, hydrazide chemistry, and
mass spectrometry. J Proteome Res. 4:2070–2080. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen R, Jiang X, Sun D, Han G, Wang F, Ye
M, Wang L and Zou H: Glycoproteomics analysis of human liver tissue
by combination of multiple enzyme digestion and hydrazide
chemistry. J Proteome Res. 8:651–661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Philippova M, Joshi MB, Kyriakakis E,
Pfaff D, Erne P and Resink TJ: A guide and guard: The many faces of
T-cadherin. Cell Signal. 21:1035–1044. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Resink TJ, Philippova M, Joshi MB,
Kyriakakis E and Erne P: Cadherins and cardiovascular disease.
Swiss Med Wkly. 139:122–134. 2009.PubMed/NCBI
|
|
11
|
Andreeva AV, Kutuzov MA, Tkachuk VA and
Voyno-Yasenetskaya TA: T-cadherin is located in the nucleus and
centrosomes in endothelial cells. Am J Physiol Cell Physiol.
297:C1168–C1177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Emond MR and Jontes JD: Inhibition of
protocadherin-alpha function results in neuronal death in the
developing zebrafish. Dev Biol. 321:175–187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haas IG, Frank M, Véron N and Kemler R:
Presenilin-dependent processing and nuclear function of
gamma-protocadherins. J Biol Chem. 280:9313–9319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Magg T, Schreiner D, Solis GP, Bade EG and
Hofer HW: Processing of the human protocadherin Fat1 and
translocation of its cytoplasmic domain to the nucleus. Exp Cell
Res. 307:100–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hou R, Liu L, Anees S, Hiroyasu S and
Sibinga NE: The Fat1 cadherin integrates vascular smooth muscle
cell growth and migration signals. J Cell Biol. 173:417–429. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferber EC, Kajita M, Wadlow A, Tobiansky
L, Niessen C, Ariga H, Daniel J and Fujita Y: A role for the
cleaved cytoplasmic domain of E-cadherin in the nucleus. J Biol
Chem. 283:12691–12700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shoval I, Ludwig A and Kalcheim C:
Antagonistic roles of full-length N-cadherin and its soluble BMP
cleavage product in neural crest delamination. Development.
134:491–501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mukherjee S, Tessema M and Wandinger-Ness
A: Vesicular trafficking of tyrosine kinase receptors and
associated proteins in the regulation of signaling and vascular
function. Circ Res. 98:743–756. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takeuchi T and Ohtsuki Y: Recent progress
in T-cadherin (CDH13, H-cadherin) research. Histol Histopathol.
16:1287–1293. 2001.PubMed/NCBI
|
|
20
|
Sato M, Mori Y, Sakurada A, Fujimura S and
Horii A: The H-cadherin (CDH13) gene is inactivated in human lung
cancer. Hum Genet. 103:96–101. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhong YH, Peng H, Cheng HZ and Wang P:
Quantitative assessment of the diagnostic role of CDH13 promoter
methylation in lung cancer. Asian Pac J Cancer Prev. 16:1139–1143.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim H, Kwon YM, Kim JS, Lee H, Park JH,
Shim YM, Han J, Park J and Kim DH: Tumor-specific methylation in
bronchial lavage for the early detection of non-small-cell lung
cancer. J Clin Oncol. 22:2363–2370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanabata T, Tsukuda K, Toyooka S, Yano M,
Aoe M, Nagahiro I, Sano Y, Date H and Shimizu N: DNA methylation of
multiple genes and clinicopathological relationship of non-small
cell lung cancers. Oncol Rep. 12:177–180. 2004.PubMed/NCBI
|
|
24
|
Toyooka KO, Toyooka S, Virmani AK,
Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF:
Loss of expression and aberrant methylation of the CDH13
(H-cadherin) gene in breast and lung carcinomas. Cancer Res.
61:4556–4560. 2001.PubMed/NCBI
|
|
25
|
Morisaki H, Yamanaka I, Iwai N, Miyamoto
Y, Kokubo Y, Okamura T, Okayama A and Morisaki T: CDH13 gene coding
T-cadherin influences variations in plasma adiponectin levels in
the Japanese population. Hum Mutat. 33:402–410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen F, Huang T, Ren Y, Wei J, Lou Z, Wang
X, Fan X, Chen Y, Weng G and Yao X: Clinical significance of CDH13
promoter methylation as a biomarker for bladder cancer: A
meta-analysis. BMC Urol. 16:522016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo Q, Wang HB, Li YH, Li HF, Li TT, Zhang
WX, Xiang SS and Sun ZQ: Correlations of promoter methylation in
WIF-1, RASSF1A, and CDH13 genes with the risk and prognosis of
esophageal cancer. Med Sci Monit. 22:2816–2824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grady WM, Willis J, Guilford PJ, Dunbier
AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, et al:
Methylation of the CDH1 promoter as the second genetic hit in
hereditary diffuse gastric cancer. Nat Genet. 26:16–17. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Andreeva AV and Kutuzov MA: Cadherin 13 in
cancer. Genes Chromosomes Cancer. 49:775–790. 2010.PubMed/NCBI
|
|
30
|
Lin YL, Xie PG and Ma JG: Aberrant
methylation of CDH13 is a potential biomarker for predicting the
recurrence and progression of non muscle invasive bladder cancer.
Med Sci Monit. 20:1572–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Widschwendter A, Ivarsson L, Blassnig A,
Müller HM, Fiegl H, Wiedemair A, Müller-Holzner E, Goebel G, Marth
C and Widschwendter M: CDH1 and CDH13 methylation in serum is an
independent prognostic marker in cervical cancer patients. Int J
Cancer. 109:163–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang J, Niu H, Huang Y and Yang K: A
systematic analysis of the relationship of CDH13 promoter
methylation and breast cancer risk and prognosis. PLoS One.
11:e01491852016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hibi K, Kodera Y, Ito K, Akiyama S and
Nakao A: Methylation pattern of CDH13 gene in digestive tract
cancers. Br J Cancer. 91:1139–1142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren JZ and Huo JR: Correlation between
T-cadherin gene expression and aberrant methylation of T-cadherin
promoter in human colon carcinoma cells. Med Oncol. 29:915–918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Toyooka S, Toyooka KO, Maruyama R, Virmani
AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio
K, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther.
1:61–67. 2001.PubMed/NCBI
|
|
36
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: Role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
37
|
Gayet O, Loncle C, Duconseil P, Gilabert
M, Lopez MB, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini
M, et al: A subgroup of pancreatic adenocarcinoma is sensitive to
the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget.
6:746–754. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang AS, Doshi KD, Choi SW, Mason JB,
Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et
al: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in
patients with leukemia. Cancer Res. 66:5495–5503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nguyen TT, Mohrbacher AF, Tsai YC, Groffen
J, Heisterkamp N, Nichols PW, Yu MC, Lübbert M and Jones PA:
Quantitative measure of c-abl and p15 methylation in chronic
myelogenous leukemia: Biological implications. Blood. 95:2990–2992.
2000.PubMed/NCBI
|
|
40
|
Blum W, Schwind S, Tarighat SS, Geyer S,
Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R,
et al: Clinical and pharmacodynamic activity of bortezomib and
decitabine in acute myeloid leukemia. Blood. 119:6025–6031. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cowan LA, Talwar S and Yang AS: Will DNA
methylation inhibitors work in solid tumors? A review of the
clinical experience with azacitidine and decitabine in solid
tumors. Epigenomics. 2:71–86. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nicholson LJ, Smith PR, Hiller L,
Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A, Schmid
P and Crook T: Epigenetic silencing of argininosuccinate synthetase
confers resistance to platinum-induced cell death but collateral
sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer.
125:1454–1463. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kuang P, Li XF, Li B, Wang YS, Li JY and
Zhou CC: Comparative proteomic analysis of human lung
adenocarcinoma A549 and A549/DDP cells. Tumor. 32:170–176.
2012.
|
|
44
|
Qin X, Yu S, Xu X, Shen B and Feng J:
Comparative analysis of microRNA expression profiles between A549,
A549/DDP and their respective exosomes. Oncotarget. 8:42125–42135.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ye LY, Hu S, Xu HE, Xu RR, Kong H, Zeng
XN, Xie WP and Wang H: The effect of tetrandrine combined with
cisplatin on proliferation and apoptosis of A549/DDP cells and A549
cells. Cancer Cell Int. 17:402017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lin YL, He ZK, Li ZG and Guan TY:
Downregulation of CDH13 expression promotes invasiveness of bladder
transitional cell carcinoma. Urol Int. 90:225–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kontic M, Stojsic J, Jovanovic D,
Bunjevacki V, Ognjanovic S, Kuriger J, Puumala S and Nelson HH:
Aberrant promoter methylation of CDH13 and MGMT genes is associated
with clinicopathologic characteristics of primary non-small-cell
lung carcinoma. Clin Lung Cancer. 13:297–303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhai X and Li SJ: Methylation of RASSF1A
and CDH13 genes in individualized chemotherapy for patients with
non-small cell lung cancer. Asian Pac J Cancer Prev. 15:4925–4928.
2014. View Article : Google Scholar : PubMed/NCBI
|
